MTOR and small cell lung carcinoma: However, a phase II trial found everolimus, an mTOR inhibitor (mTORi) approved for multiple neoplasms, had only limited antitumor activity in relapsed SCLC, suggesting a need to combine this drug with other therapeutics (13).